These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11561989)

  • 1. Can chemotherapy alter the course of prostate cancer?
    Haas NB
    Semin Urol Oncol; 2001 Aug; 19(3):212-21. PubMed ID: 11561989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
    J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of chemotherapy in advanced prostate cancer.
    Ernst DS
    Can J Urol; 2002 Jun; 9 Suppl 1():21-5. PubMed ID: 12121591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
    Sleijfer S; Stoter G
    Nat Clin Pract Oncol; 2005 Feb; 2(2):70-1. PubMed ID: 16264874
    [No Abstract]   [Full Text] [Related]  

  • 7. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
    Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
    Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
    Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
    Petrylak DP
    Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
    Oh WK; Kantoff PW
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP
    Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
    Mackler NJ; Pienta KJ; Dunn RL; Cooney KA; Redman BG; Olson KB; Fardig JE; Smith DC
    Clin Genitourin Cancer; 2007 Jun; 5(5):318-22. PubMed ID: 17645828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
    Petrylak DP; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):28-33. PubMed ID: 10604266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
    Protheroe A
    Nat Clin Pract Oncol; 2005 Feb; 2(2):68-9. PubMed ID: 16264873
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hormone refractory prostate cancer.
    Knox JJ; Moore MJ
    Semin Urol Oncol; 2001 Aug; 19(3):202-11. PubMed ID: 11561988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in chemotherapy of prostate cancer.
    Heicappell R
    Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.